retatrutide nejm 2023 obesity trial ly3437943 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Phase 2 Trial of Retatrutide

doi:10.1080/23293691.2025.2545308

Taking Ozempic or metformin isnt right for everyone

But for wellness-focused high performers, the reality has been less appealing

Time injections thoughtfully based on your schedule and how your body responds

"We found that GLP-1RA is good in maintaining neuronal survival during a stroke and the phase two study indicated preliminary evidence that GLP-1RA therapy might improve stroke patients' prognosis up to a 24-hour window

Participants in the SGLT2i group demonstrated improvement in renal function with an increase in mean eGFR over the 5-year follow-up period (+3.5 ml/min per 1.73 m 2 ), compared with an overall reduction in eGFR in the GLP-1 RA cohort (7.2 ml/min per 1.73 m 2 )